logo
welcome
Reuters

Reuters

Illumina expects full-year sales from core segment to decline on biotech funding crunch

Reuters
Summary
Nutrition label

82% Informative

Illumina has seen sluggish demand for its tools and services from key markets such as China and cautious spending from its customers such as biotechnology companies.

Core Illumina revenue to decline 2% to 3% , compared to the previous year .

Analysts expect full-year adjusted profit of $ 3.91 per share for the whole company.

VR Score

93

Informative language

99

Neutral language

72

Article tone

semi-formal

Language

English

Language complexity

54

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links